ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
82.07
-2.82 (-3.32%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close84.89
Open85.06
Bid80.00 x 1100
Ask86.50 x 1400
Day's Range79.80 - 86.20
52 Week Range60.27 - 124.22
Volume1,287,468
Avg. Volume765,819
Market Cap8.735B
Beta (3Y Monthly)2.44
PE Ratio (TTM)N/A
EPS (TTM)-7.57
Earnings DateMay 1, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est123.72
Trade prices are not sourced from all markets
  • Here is What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY)
    Insider Monkey48 minutes ago

    Here is What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY)

    "Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]

  • Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
    Zacks3 days ago

    Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran

    Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.

  • Is Alnylam Pharmaceuticals a Buy Now?
    Motley Fool3 days ago

    Is Alnylam Pharmaceuticals a Buy Now?

    Everything's falling into place for the pioneer of RNA interference.

  • Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
    Zacks4 days ago

    Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran

    Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.

  • Business Wire4 days ago

    Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the Company has initiated ILLUMINATE-B, a global Phase 3 pediatric study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1 (PH1). The study will enroll approximately eight patients with PH1 under six years of age. The primary endpoint is the percent reduction in urinary oxalate from baseline to six months.

  • Business Wire7 days ago

    Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today positive complete results from the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP).

  • 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
    Zacks8 days ago

    4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

    We take a look at companies, which have been developing treatments for various diseases using RNAi technology.

  • Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More
    Zacks9 days ago

    Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More

    Key highlights of the past week are new drug approvals, collaborations and pipeline updates.

  • Markit10 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNYView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for ALNY with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $1.16 billion over the last one-month into ETFs that hold ALNY are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics
    Zacks10 days ago

    Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics

    Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).

  • Benzinga11 days ago

    Regeneron, Alnylam Strike $1B Collaboration For RNAi-based Therapeutics

    In a biotech tie-up, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a collaboration agreement Monday with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Regeneron and Alnylam said they will exclusively collaborate on discovering, developing and commercializing new RNA interface — or RNAi — therapeutics for a broad range of disease targets expressed in the eye and central nervous system. The companies will also work on therapies for a select number of targets expressed in the liver. The agreement has Regeneron paying $400 million upfront to Alnylam and buying up to $400 million worth of Alnylam stock at $90 per share.

  • Reuters11 days ago

    Regeneron forays into gene-silencing therapies with Alnylam tie-up

    Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology. Alnylam, which last year won U.S. approval for the first treatment using the Nobel prize-winning technology, has a host of other such therapies in its pipeline for various genetic, cardio-metabolic, liver and eye and central nervous system (CNS) diseases. Regeneron will make a $400 million upfront payment to Alnylam and also purchase 4.44 million of Alnylam common shares at $90 per share.

  • Alnylam trades partner Sanofi for Regeneron in $800M deal
    American City Business Journals11 days ago

    Alnylam trades partner Sanofi for Regeneron in $800M deal

    Cambridge gene therapy firm Alnylam is changing alliances, cutting research ties with longtime partner Sanofi and teaming up with Regeneron on new eye and central nervous system treatments.

  • What Do Analysts Think About Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Earnings Trajectory?
    Simply Wall St.11 days ago

    What Do Analysts Think About Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Earnings Trajectory?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The latest earnings update Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released in December 2018 suggested...

  • Business Wire11 days ago

    Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, and Regeneron Pharmaceuticals, Inc. (REGN), announced today a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver. Under the terms of the alliance, Alnylam will work exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases. Regeneron will lead development and commercialization for all programs targeting eye diseases, with Alnylam entitled to potential milestone and royalty payments.

  • PR Newswire11 days ago

    Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

    Regeneron Pharmaceuticals, Inc. (REGN) and Alnylam Pharmaceuticals, Inc. (ALNY) today announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver. The collaboration will leverage both companies' scientific and technological expertise and will build on Alnylam's recent preclinical data showing potent and highly durable delivery of RNAi therapeutics to achieve target gene silencing in the eye and CNS. Under the terms of the alliance, Alnylam will work exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases.

  • Business Wire11 days ago

    Alnylam and Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that Alnylam and Sanofi have agreed to conclude the research and option phase of the companies’ 2014 RNAi therapeutics alliance in rare genetic diseases. “Our landmark 2014 rare disease alliance with Sanofi resulted in the advancement of three Phase 3 programs – patisiran, vutrisiran, and fitusiran – and the global launch of ONPATTRO, the world’s first RNAi therapeutic.

  • 2 Biotechs With Big Dates in April
    Motley Fool20 days ago

    2 Biotechs With Big Dates in April

    Here's what you need to know about two biotechs that will present trial results that could send their stock prices soaring -- or plummeting.

  • Business Wire23 days ago

    Alnylam to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress™

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the Company and its collaborators will present at the European Association for the Study of the Liver (EASL) 54th Annual International Liver Congress™, being held April 10-14, 2019 in Vienna, Austria. Presentations include full clinical results from the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP).

  • Alnylam's (ALNY) Impressive Pipeline Drives Share Price
    Zackslast month

    Alnylam's (ALNY) Impressive Pipeline Drives Share Price

    Alnylam's (ALNY) share price increases on robust performance of pipeline candidates.

  • Alnylam Files Application for Hypertension Candidate in UK
    Zackslast month

    Alnylam Files Application for Hypertension Candidate in UK

    Alnylam (ALNY) submits a CTA application to The Medicines and Healthcare products Regulatory Agency in the United Kingdom for ALN-AGT for the treatment of uncontrolled hypertension.